Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

BRACE CORONA, 2020 RCTdiscontinuation of ACEI/ARBcontrolCOVID 19 hospitalizedsome concern
334/325 inconclusive
    REPLACE, 2020
     
    NCT04338009
    RCTRenin-angiotensin-system-acting agentscontrolCOVID 19 hospitalizedNA
    77/75 inconclusive

      COVID 19 all comers meta-analysis

      Li, 2020 OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comerscritical
      -/- inconclusive
        Meng, 2020 OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comerscritical
        17/25 inconclusive
          Yang, 2020 OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
          43/83 inconclusive
            Zhang, 2020 OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
            188/940 suggested
            • suggested 63 % decrease in deaths but with a low degree of certainty due to high risk of bias
            Bean, 2020 OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
            37/168 suggested
            • suggested 71 % decrease in death or transfer to ICU but with a low degree of certainty due to high risk of bias
            Yan et al., 2020 OBSangiotensin receptor blockers (ARBs)controlCOVID 19 all comerscritical
            -/- inconclusive
              Yan et al., 2020 OBSangiotensin converting enzyme inhibitors (ACEIs)controlCOVID 19 all comerscritical
              -/- inconclusive

                PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).